Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ + T cells targeting multiple myeloma

Jooeun Bae, Shuichi Kitayama, Zach Herbert, Laurence Daheron, Keiji Kurata, Derin B. Keskin, Kenneth Livak, Shuqiang Li, Mubin Tarannum, Rizwan Romee, Mehmet Samur, Nikhil C. Munshi, Shin Kaneko, Jerome Ritz, Kenneth C. Anderson

Blood (2024) 143 (10): 895–911.

https://doi.org/10.1182/blood.2023020528

Published: 2024

Includes: Supplemental data

Journal Articles

Rejuvenated BCMA-Specific CD8 + Cytotoxic T Lymphocytes Derived from Antigen-Specific Induced Pluripotent Stem Cells : Immunotherapeutic Application in Multiple Myeloma

Jooeun Bae, Shuichi Kitayama, Laurence Daheron, Zach Herbert, Nikhil C. Munshi, Shin Kaneko, Jerome Ritz, Kenneth C. Anderson

Blood (2021) 138 (Supplement 1): 75.

https://doi.org/10.1182/blood-2021-153110

Published: 2021

Journal Articles

Development TACI and Bcma Dual-Antigen Targeted Immunotherapy for Multiple Myeloma

Jooeun Bae, PhD, Teru Hideshima, MD PhD, Mehmet Kemal Samur, PhD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 3138.

https://doi.org/10.1182/blood-2019-128689

Published: 2019

Journal Articles

Bcma Heteroclitic Peptide Encapsulated Nanoparticle Enhances Antigen Stimulatory Capacity and Tumor-Specific CD8 + cytotoxic T Lymphocytes Against Multiple Myeloma

Jooeun Bae, PhD, Parayath Neha, Mansoor Amiji, Nikhil Munshi, MD, Kenneth Anderson, MD

Blood (2018) 132 (Supplement 1): 3195.

https://doi.org/10.1182/blood-2018-99-117292

Published: 2018

Journal Articles

Selective Targeting of Multiple Myeloma By Bcma-Specific Central Memory CD8 + cytotoxic T Lymphocytes: A Potential Immunotherapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders

Jooeun Bae, PhD, Teru Hideshima, MD PhD, Nikhil Munshi, MD, Kenneth C. Anderson, MD

Blood (2018) 132 (Supplement 1): 3196.

https://doi.org/10.1182/blood-2018-99-117282

Published: 2018

Journal Articles

Pembrolizumab (anti-PD-1) Treatment Increases Anti-Tumor Activities of XBP1/CD138/CS1-Specific Cytotoxic T Lymphocytes Against Multiple Myeloma

Jooeun Bae, PhD, Derin Keskin, PhD, Yu-Tzu Tai, PhD, Teru Hideshima, MD PhD, Nikhil Munshi, MD, Kenneth C Anderson, MD

Blood (2017) 130 (Supplement 1): 1867.

https://doi.org/10.1182/blood.V130.Suppl_1.1867.1867

Published: 2017

Journal Articles

Identification and Validation of HLA-A24 XBP1 us , XBP1 sp , CD138, and CS1 Peptides to Generate Antigens Specific-Cytotoxic T Lymphocytes: Preclinical Basis for Vaccine Therapy in HLA-A24 Patients with Multiple Myeloma and Other Cancers

Jooeun Bae, PhD, Brandon Nguyen, Matthew Ho, Yan Song, PhD, Noopur Raje, MD, Paul G. Richardson, MD, Teru Hideshima, MD PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 5689.

https://doi.org/10.1182/blood.V128.22.5689.5689

Published: 2016

Journal Articles

Anti-Tumor Activities of XBP1 Antigen-Specific Cytotoxic T Lymphocytes Are Enhanced By HDAC6 Inhibitor ACY241

Jooeun Bae, PhD, Matthew Ho, Brandon Nguyen, Arghya Ray, PhD, Dharminder Chauhan, PhD, Teru Hideshima, MD PhD, Nikhil Munshi, MD, Kenneth C Anderson, MD

Blood (2016) 128 (22): 2143.

https://doi.org/10.1182/blood.V128.22.2143.2143

Published: 2016

Journal Articles

Induction of T Cell Immunity Using a Multipeptide Cocktail Containing XBP1, CD138 and CS1 Peptides in Smoldering Multiple Myeloma

Jooeun Bae, PhD, Rao H. Prabhala, Ph.D., Weihua Song, MD, Yu-Tzu Tai, PhD, Kenneth C. Anderson, Nikhil C Munshi, MD

Blood (2012) 120 (21): 5039.

https://doi.org/10.1182/blood.V120.21.5039.5039

Published: 2012

Journal Articles

Novel Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders,

Jooeun Bae, Ph.D., Ruben Carrasco, MD, PhD, Ann-Hwee Lee, Ph.D., Rao Prabhala, Ph.D., Yu-Tzu Tai, PhD, Weihua Song, MD, Kenneth C Anderson, MD, Nikhil C. Munshi, MD

Blood (2011) 118 (21): 3990.

https://doi.org/10.1182/blood.V118.21.3990.3990

Published: 2011

Journal Articles

Hsp90 Is Critical for the Regulation of Phenotype and Functionality of Human Dendritic Cells.

Jooeun Bae, PhD, Constantine Mitsiades, MD, Tai Yu-Tzu, PhD, Jeff Martinson, BS, Ramesh Babu Batchu, PhD, Robert Bertheau, BS, Cheng Li, PhD, Rao Prabhala, Shammas Masood, Teru Hideshima, Lawrence Catley, Kenneth Anderson, Nikhil Munshi

Blood (2005) 106 (11): 2401.

https://doi.org/10.1182/blood.V106.11.2401.2401

Published: 2005

Journal Articles

Hsp90 Is Critical for the Regulation of Human T Lymphocytes and NK Cell Phenotype and Function.

Jooeun Bae, PhD, Constantine Mitsiades, M.D., Rao Prabhala Prabhala, PhD, Tai Yu-Tzu, PhD, Jeff Martinson, BS, Steven Hartson, PhD, Teru Hideshima, PhD, Lawrence Catley, M.D., Xianfeng Li, BS, Ramesh Babu Batchu, PhD, Robert Bertheau, BS, Shammas Masood, PhD, Sushima Samala, M.S., Jeff Miller, PhD, Kenneth Anderson, M.D., Nikhil Munshi, M.D.

Blood (2005) 106 (11): 3464.

https://doi.org/10.1182/blood.V106.11.3464.3464

Published: 2005

Journal Articles

Development of Novel CD138 Antigen-Specific Peptide Capable of Eliciting Myeloma-Specific Cytotoxic T Lymphocytes Response.

Jooeun Bae, PhD, Jeff Martinson, BS, Tai Yu-Tzu, PhD, Paola Neri, MD, Pierfrancesco Tassone, MD, Xianfeng Li, BS, Rory Coffey, BS, Zhinan Xia, PhD, Rao Prabhala, PhD, Kenneth Anderson, MD, Nikhil Munshi, MD

Blood (2005) 106 (11): 3465.

https://doi.org/10.1182/blood.V106.11.3465.3465

Published: 2005

Journal Articles

Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications.

Yu-Tzu Tai, PhD, Laurence Catley, MD, Xian-Feng Li, MS, Rory Coffey, BS, Iris Breitkreutz, MD, Jooeun Bae, PhD, Klaus Podar, MD, PhD, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Robert Schlossman, MD, Paul Richardson, MD, Steven P. Treon, MD, PhD, Iqbal S. Grewal2, PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 5150.

https://doi.org/10.1182/blood.V106.11.5150.5150

Published: 2005

Journal Articles

XBP-1 a Selective and Specific Target for Immunotherapy in Myeloma.

Jooeun Bae, PhD, Ruben Carrasco, PhD, Kumar Sukhdeo, PhD, Pierfrancesco Tassone, MD, Paola Neri, MD, Tai Yu-Tzu, PhD, Xianfeng Li, BS, Rory Coffey, BS, Rao Prabhala, PhD, Kenneth Anderson, MD, Nikhil Munshi, MD

Blood (2005) 106 (11): 1594.

https://doi.org/10.1182/blood.V106.11.1594.1594

Published: 2005

Journal Articles

The Polycomb Group Transcriptional Repressor Bmi-1 Is Constitutively Expressed in Multiple Myeloma (MM) Cells and Modulates Proliferation through a Mechanism Independent of the Ink4a/ARF Locus.

Frank J. Desarnaud, Ph.D, Masood Shammas, Ph.D, Paola Neri, MD, Hemanta Koley, Ph.D, Rao Prabhala, Ph.D, Li Cheng, Ph.D, Suk Kim Ryung, Dharminder Chauhan, Ph.D, Pierfrancesco Tassone, MD, Jooeun Bae, Ph.D, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2004) 104 (11): 3346.

https://doi.org/10.1182/blood.V104.11.3346.3346

Published: 2004

Journal Articles

Dysregulated CD4 + CD25 + T- Regulatory Cells and TLRs in Myeloma.

Rao Prabhala, PhD, Paola Neri, MD, Pierfrancesco Tassone, MD, Masood A. Shammas, PhD, Jooeun Bae, PhD, Virginia M. Cumming, Charles K. Allam, MD, John F. Daley, PhD, Frank Desarneud, PhD, Dharminder Chauhan, PhD, Elizabeth Blanchard, MD, Kenneth Anderson, MD, Nikhil C. Munshi, MD

Blood (2004) 104 (11): 2466.

https://doi.org/10.1182/blood.V104.11.2466.2466

Published: 2004

Journal Articles

Induction of Multiple Myeloma-Specific Cytotoxic T Lymphocytes Using HLA-A2.1-Specific CD19 and CD20 Peptides.

Jooeun Bae, Ph.D., Jeff A. Martinson, B.S., Hans G. Klingemann, M.D., Steven Treon, M.D., Kenneth C. Anderson, M.D., Nikhil C. Munshi, M.D.

Blood (2004) 104 (11): 2477.

https://doi.org/10.1182/blood.V104.11.2477.2477

Published: 2004

NARROW

Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ + T cells targeting multiple myeloma

Rejuvenated BCMA-Specific CD8 + Cytotoxic T Lymphocytes Derived from Antigen-Specific Induced Pluripotent Stem Cells : Immunotherapeutic Application in Multiple Myeloma

Development TACI and Bcma Dual-Antigen Targeted Immunotherapy for Multiple Myeloma

Bcma Heteroclitic Peptide Encapsulated Nanoparticle Enhances Antigen Stimulatory Capacity and Tumor-Specific CD8 + cytotoxic T Lymphocytes Against Multiple Myeloma

Selective Targeting of Multiple Myeloma By Bcma-Specific Central Memory CD8 + cytotoxic T Lymphocytes: A Potential Immunotherapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders

Pembrolizumab (anti-PD-1) Treatment Increases Anti-Tumor Activities of XBP1/CD138/CS1-Specific Cytotoxic T Lymphocytes Against Multiple Myeloma

Identification and Validation of HLA-A24 XBP1 us , XBP1 sp , CD138, and CS1 Peptides to Generate Antigens Specific-Cytotoxic T Lymphocytes: Preclinical Basis for Vaccine Therapy in HLA-A24 Patients with Multiple Myeloma and Other Cancers

Anti-Tumor Activities of XBP1 Antigen-Specific Cytotoxic T Lymphocytes Are Enhanced By HDAC6 Inhibitor ACY241

Induction of T Cell Immunity Using a Multipeptide Cocktail Containing XBP1, CD138 and CS1 Peptides in Smoldering Multiple Myeloma

Novel Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders,

Hsp90 Is Critical for the Regulation of Phenotype and Functionality of Human Dendritic Cells.

Hsp90 Is Critical for the Regulation of Human T Lymphocytes and NK Cell Phenotype and Function.

Development of Novel CD138 Antigen-Specific Peptide Capable of Eliciting Myeloma-Specific Cytotoxic T Lymphocytes Response.

Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications.

XBP-1 a Selective and Specific Target for Immunotherapy in Myeloma.

The Polycomb Group Transcriptional Repressor Bmi-1 Is Constitutively Expressed in Multiple Myeloma (MM) Cells and Modulates Proliferation through a Mechanism Independent of the Ink4a/ARF Locus.

Dysregulated CD4 + CD25 + T- Regulatory Cells and TLRs in Myeloma.

Induction of Multiple Myeloma-Specific Cytotoxic T Lymphocytes Using HLA-A2.1-Specific CD19 and CD20 Peptides.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only